CEO Miles White

Abbott Laboratories (ABT) (ABT) bid to expand use of its best-selling arthritis treatment Humira to ulcerative colitis patients is being delayed by U.S. regulators. We did receive a complete response letter several months ago and have provided additional information to the Food and Drug Administration, Elizabeth Hoff, a spokeswoman for the Abbott Park, Illinois-based company, said in an e-mail today...  

Hawaii has joined 44 other states and the District of Columbia in a $100 million settlement with Abbott Laboratories over the pharmaceutical company's promotion of the anti-seizure and mood-stabilizing drug Depakote. KITV reports Hawaii will receive nearly $1.2 million and Illinois-based Abbott (NYSE: ABT) will be restricted from marketing the drug for uses that are not approved by the U.S. Food and Drug Administration. The Associated Press...  

Florida will receive $5 million of a $100 million settlement with Abbott Laboratories over allegations of illegal off-label marketing of the drug Depakote. The $5 million will go toward future consumer protection efforts, Florida Attorney General Pam Bondi said in a written statement. Bondi and attorney generals from 44 other states alleged Abbott engaged in unfair and deceptive practices in marketing Depakote for off-label uses. The drug...  

Abbott Laboratories agreed to pay $1.6 billion as part of a settlement to resolve allegations that the company improperly promoted its antiseizure drug Depakote for unauthorized uses, The Wall Street Journal reported. Abbott admitted that from 1998 through 2006, it had a specialized sales force trained to market Depakote in nursing homes for the treatment of aggression and agitation in elderly dementia patients, despite the absence of...  

By ValueMax:The pharmaceuticals industry is a defense play, just like the food and beverages industry, in terms of sensitivity and market beta. Abbott Laboratories (ABT) is uniquely situated in the industry because of its growth prospects and because it still has a reduced valuation due to lawsuit-related uncertainty. The month of May brought the end to a lawsuit filed against the company for marketing Depakote, a drug for schizophrenia, for...  

St. Jude Medical Inc. and Abbott Laboratories Inc. will extend and expand a joint marketing arrangement, the medical-device makers announced Monday. Under terms of the new multi-year agreement, Abbott will now promote two additional St. Jude therapies: Its fractional flow reserve (FFR) technology, which physicians use to assess blood-flow blockages in arteries, and its optical coherence tomography (OCT) products, which cardiologists use to...  

The ongoing debate concerning the efficacy of fenofibrate has overshadowed an important aspect of the drug's history: Abbott Laboratories, the maker of branded fenofibrate, has produced several bioequivalent reformulations that dominate the market, although generic fenofibrate has been available for almost a decade. This continued use of branded formulations, which cost twice as much as generic versions of fenofibrate, imposes an annual cost...  

The state of Ohio on Monday provided a $1.6 million grant to go toward construction on the Abbott Laboratories plant in Tipp City, expected to create 240 jobs. The grant comes from the Ohio Department of Development through its Ohio Jobs Ready Site Program, which awards grants for commercial and industrial projects with potential to attract businesses and optimize infrastructure. Additionally, the state controlling board approved a $600,000...  

After more than a dozen years, Abbott Laboratories is no longer operating under a consent decree. The settlement was made in 1999 after a remarkable six-year run of manufacturing deficiencies and subsequent failures to fix various problems in its diagnostics division. The decree was terminated last month, according to an Abbott spokeswoman. The move came after the drug and device maker was able to...  

Abbott Laboratories (ABT) is making a case that it's a serious contender to develop a better drug to treat the liver-destroying virus hepatitis C. In a pair of small studies Abbott showed that its experimental pills taken with other drugs can cure more than 90% of patients with the virus. In one trial closely watched by investors dubbed Co-Pilot two groups of patients showed 95% and 93% cure rates when given the Abbott drugs. Abbott said the...  

Connecticut will receive approximately $6 million of the $1.6 billion that Abbott Laboratories will pay in federal and state civil and criminal settlements surrounding allegations that it improperly marketed the neurologic medication Depakote for off-label uses, The Waterbury Republican-American reports.  

Tennessee will get $5 million more from the $1.6 billion settlement with Abbott Laboratories, The Tennessean reports. The additional $5 million is on top of $2 million that was announced Monday for the state. Illinois-based Abbott is making the massive payout to settle allegations that it deceptively marketed an anti-seizure drug, Depakote, for unapproved uses.  

Ohio development leaders approved a $1.5 million loan for Abbott Laboratories, which it plans to put toward machinery and equipment for its upcoming Tipp City plant, the pharmaceutical giant's first Dayton-area operation. Abbott announced this month it would build a $270 million manufacturing plant in Miami County and employ 240 workers at the site. On Monday, the Development Financing Authority Council, through the Ohio Department of...  

Tennessee will get a $1.95 million share of a $1.6 billion settlement with Abbott Laboratories over deceptive marketing practices involving an anti-seizure drug, The Associated Press reports. The drug, Depakote, has been approved to treat seizures, migraine headaches and mania associated with bipolar disorder. But governments across the U.S. alleged it was marketed to treat certain conditions for which it wasn't approved, including...  

Abbott Laboratories will pay New York and 45 other states $100 million to resolve allegations that it improperly marketed the drug Depakote. Depakote is approved by the U. S. Food and Drug Administration to treat seizure disorders, mania associated with bipolar disorder and prophylaxis of migraines. Attorneys general allege that Abbott representatives engaged in unfair and deceptive practices by marketing Depakote for off-label uses...  

Abbott Laboratories pleaded guilty and agreed to pay $1.5 billion over allegations it marketed the anti-seizure drug Depakote for uses that were not approved by the U.S. Food and Drug Administration. Arizona joined 44 other states and the District of Columbia in a $100 million settlement with Chicago-based Abbott. The wider case also included a criminal fine and forfeiture of $700 million and civil settlements with the federal government and...  

BOISE -- Idaho will receive more than $1 million as part of a near-record settlement over prescription drug misbranding. The U.S. Justice Department today announced that Abbott Laboratories will pay a total of $1.5 billion in criminal and civil penalties for illegal promotion of the drug Depakote. The FDA approved the drug for treatment of seizure disorders, bipolar disorder and prevention of migraines. Abbott has pleaded guilty to charges of...  

Global health care company Abbott Laboratories reached its 2015 goals for carbon dioxide emissions, water intake and waste output in 2011, while increasing year-on-year sales by more than 10 percent. In 2009 the company committed to a 15 percent reduction of its absolute Scope 1 and Scope 2 carbon dioxide emissions over 2005 levels by [...]  

Global pharmaceutical giant Abbott Laboratories has agreed to pay federal and state governments $1.6 billion in criminal and civil fines for illegally promoting unapproved uses of its drug Depakote, including to sedate elderly patients in nursing homes, officials announced Monday. Read full article >>  

Case resolves company's wrongful marketing of prescription drug DepakoteAUGUSTA - Attorney General Schneider and the attorneys general of 44 other states and the District of Columbia today announced a $100 million settlement with Abbott Laboratories over allegations of illegal off-label marketing of its Depakote drug. The agreement marks the largest consumer protection-based pharmaceutical settlement ever reached. Maine will receive nearly $1...  

Abbott Laboratories has agreed to plead guilty to fraud in connection with its marketing of the drug Depakote, which the federal government has said the company promoted to treat conditions that it was not approved for.Contributor: Vanessa EvansPublished: May 07, 2012  

In the second-largest payment ever by a drug company, Abbott Laboratories agreed today to pay $1.5 billion and enter a guilty plea in federal district court in Virginia for unlawfully marketing one of its medications to seniors for off-label uses....  

Abbott Laboratories will pay Wisconsin and 45 other states $100 million to resolve allegations that it improperly marketed the drug Depakote, Attorney General J.B. Van Hollen’s office said in a news release Monday. Depakote is approved by the U.S. Food and Drug Administration to treat seizure disorders, mania associated with bipolar disorder and prophylaxis of migraines. Van Hollen and the other attorneys general allege that Abbott...  

Idaho will get $1.2 million as part of a $100 million settlement with 44 states and Washington D.C. from Abbott Laboratories, Idaho Attorney General Lawrence Wasden said Monday.Click to Continue »  

In a decision that bolsters the pharmaceutical industry, a federal appeals court has ruled that sales reps are not eligible for overtime pay. In doing so, the court also rejected the position taken by the US Department of Labor, which has filed briefs in numerous cases supporting the notion that sales reps are entitled to overtime. The ruling by the Seventh Circuit Court of Appeals combined cases involving...  

FRANKFORT, Ky. (AP) -- Kentucky will receive $4.6 million as part of a legal settlement with Abbott Laboratories. Attorney General Jack Conway announced Kentucky's share from the settlement on Monday. The Illinois-based company agreed to pay $1 ...  

As Abbott Laboratories prepares to get down to basics as a consumer-products company, it is pinning its emerging-market ambitions in part on turmeric. And cumin and chili. Abbott, which will split with its 124-year-old research-based drug division later this year, is shifting its focus from breakthrough medicines like arthritis treatment Humira, which command high prices in developed markets, to more...  

Abbott Laboratories (ABT) has encountered a delay in its bid for U.S. regulatory approval to expand the uses of its blockbuster anti-inflammatory drug Humira to include treatment of the bowel disease ulcerative colitis. Abbott received a ...  

In a move that is sure to raise debate about the path forward for biosimilars, Abbott Laboratories has filed a citizens petition with the FDA in which the drugmaker asks the agency not to approve any biosimilar for its Humira treatment for rheumatoid arthritis. On what grounds? Abbott argues that the FDA would have no choice but to use trade secrets submitted to the agency when approval for Humira...  

ABBOTT PARK, Ill. and AARHUS, Denmark, May 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac...  

Texas Attorney General Greg Abbott and other state attorneys general today resolved a two-phase Medicaid fraud and deceptive marketing investigation into Abbott Laboratories. The investigation centered on the unlawful promotional scheme that Abbott Laboratories launched to increase the sales of its anti-seizure drug Depakote.  

COPENHAGEN, May 3, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, announces that a license agreement has been signed with Abbott for the further development and commercialization of AP214 (referred to as ZP1480 by Zealand Pharma). AP214 (ZP1480) is a first-in-class melanocortin peptide...  

Abbott Laboratories (ABT) (ABT)’ bid to expand use of its best-selling arthritis treatment Humira to ulcerative colitis patients is being delayed by U.S. regulators. “We did receive a complete response letter several months ago and have ...  

Abbott Laboratories operates in the Biotechnology & Drugs industry, a subset of the Healthcare sector. The firm has a market capitalization of 89011.13 million, and 91000 employees. Currently, 25 Wall Street Analysts cover the firm, including Alpha Street ...  

DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/rwrbqc/abbott_enters_into) has announced the addition of GlobalData 's new company profile "Abbott Enters into Licensing and Supply Agreement with Zydus Cadila" to their offering. The report provides information on the strategic split of Abbott Laboratories into two diversified companies, medical products and research-based pharmaceutical company...  

Tennessee will get a small portion of a massive $1.5 billion penalty agreed to by drug maker Abbott Laboratories on Monday in connection with how it marketed a major anti-seizure drug. Abbott has pleaded guilty and agreed to pay $1.5 billion ...  

AUSTIN - Texas Attorney General Greg Abbott and other state attorneys general today resolved a two-phase Medicaid fraud and deceptive marketing investigation into Abbott Laboratories....  

Drug-maker Abbott Laboratories pleaded guilty in federal court Monday to illegally marketing an anti-seizure medication for unapproved purposes, and agreed to pay $1.5 billion in civil and criminal penalties that will include costs incurred by Virginia ...  

Washington (CNN)-- Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote, the U.S. Justice Department said Monday.  

CHICAGO - Abbott Laboratories will pay $1.6 billion to settle federal and state claims that it improperly marketed the neurologic medication Depakote for off-label uses, the company said Monday. read more  

Drugmaker improperly marketed anti-seizure medication for off-label uses, or those not approved by the FDA Abbott Laboratories said Monday that it will pay $1.6 billion to settle federal and state claims that it illegally marketed the anti-seizure medication Depakote for uses not approved by the Food and Drug Administration.  

Global pharmaceutical giant Abbott Laboratories has agreed to pay federal and state governments $1.6 billion in criminal and civil fines for illegally promoting unapproved uses of its drug Depakote, including to sedate elderly patients in nursing homes, officials announced Monday. Read full article >>  

CHICAGO--(BUSINESS WIRE)--Fitch Ratings has placed Abbott Laboratories' (ABT's) Long-term ratings on Negative Watch. In addition, Fitch has affirmed ABT's Short-term ratings at 'F1'. A full list of ABT's ratings follows at the end of this press release.  

AUSTIN – Texas Attorney General Greg Abbott and other state attorneys general today resolved a two-phase Medicaid fraud and deceptive marketing investigation into Abbott Laboratories. YouTube Video:  No YouTube read more  

Once again, another big US health care organization is set to make a (monetarily) huge legal settlement.  As reported by Bloomberg, Abbott Laboratories will settle allegations about its marketing of Depakote (valproic acid), nominally an anti-seizure medication:Abbott Laboratories (ABT) (ABT) said it will pay $1.6 billion to settle federal and state claims resulting from an investigation into its epilepsy medication Depakote, the second...  

Abbott Laboratories (ABT), splitting into a drugmaker and a diversified health-care business, reported net income that beat analysts estimates and raised its 2012 forecast as sales jumped more than expected for its top product.First-quarter revenue climbed 4.6 percent to $9.46 billion in the quarter, the Abbott Park, Illinois-based company said in a statement today. Humira, an autoimmune...  

ABBOTT PARK, Ill., and WATERTOWN, Mass., April 19, 2012 /PRNewswire/ --Abbott(NYSE: ABT)and Enanta Pharmaceuticals announced data from "Co-Pilot," an interferon-free, Phase 2 study of Abbott's direct-acting antiviral medicines for the treatment of hepatitis C (HCV) that found that more than 90 percent of patients...  

In what the Justice Department has declared to be one of the largest payments by a drug company in U.S. history, Abbott Laboratories was ordered on Monday to pay a combination of criminal fines and civil settlements totaling more than $1.5 billion. The company previously pleaded guilty to marketing its drug Depakote for uses which the Food and Drug Administration had not approved, according to ...  

CNN - Found 16 hours ago(CNN) -- Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote, the U.S. Justice Department announced Monday. The figure is the second-largest payment ever by a ... Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion...  

They will split about $84 million from the settlement, Heaphy said. The case was investigated by the Virginia Attorney General's Medicaid Fraud Control Unit and prosecuted by the U.S. attorney's office in Western Virginia because of their track records ...  

ABBOTT PARK, Ill., April 17, 2012 /PRNewswire/ --Abbott (NYSE: ABT) announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG). The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically...  

Abbott pleaded guilty to misbranding Depakote by promoting the drug to control agitation and aggression in patients with elderly dementia and to treat schizophrenia when neither use was approved by the Food and Drug Administration, the Justice ...  

Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery ... Nutrition Products In India 12:54a DJ Abbott Ties Up With ...  

Applicable Criteria and Related Research: --'Corporate Rating Methodology' (Aug. 12, 2011); --'For-Profit Hospital Quarterly Diagnosis: Fourth Quarter 2012' (April 25, 2012); --'Navigating the Drug Channel- Long-Term Care Pharmacies: At the ...  

Looking at the universe of stocks we cover at Dividend Channel, on 4/11/12, Abbott Laboratories (NYSE: ABT) will trade ex-dividend, for its quarterly dividend of $0.51, payable on 5/15/12. As a percentage of ABT's recent stock price of $60.71, this dividend works out to approximately 0.84%.  

Abbott Laboratories' $9-billion arthritis drug Humira is set to take the crown as the world's top-selling medicine this year, highlighting the dominance of costly biotechnology products as revenues from old-style pills decline. Neither of last year's biggest sellers - Pfizer's cholesterol fighter Lipitor or blood thinner Plavix from Sanofi and Bristol-Myers Squibb - will even make it into the top ...  

US - IL - Chicago, The incumbent must be able to act independently and demonstrate sound business judgment within the scope of broad guidelines. This position has authority to represent PPD and to commit the Company to  

MUMBAI: Abbott Laboratories will collaborate with Bangalore-based Biocon to establish a research and development centre to develop nutrition products in India. Abbott Nutrition Centre, India will work with Syngene, the contract research arm of ...  

Construction is to start immediately by Abbott Laboratories on a $270 million project to build a nutritional drinks manufacturing plant in Tipp City, the company said Monday following approval of a state incentive package.  

Acting Associate Attorney General Tony West said it was case of Abbott ... providers seriously and has established robust compliance programs to ensure its marketing programs meet the needs of health care providers and legal requirements."  

Maine will benefit from a settlement reached Monday over allegations a pharmaceutical lab promoted an anti-seizure drug for uses that were not approved by the Food and Drug Administration.  

"These settlements were the result of hard work and cooperation at both the federal and state levels," Connecticut Attorney General George Jepsen said in an announcement about the settlement. "They will serve as a deterrent to other companies ...  

By Dividend Growth Investor:In a previous article, I discussed how dividend investors should analyze the earnings of each company they own in detail, in order to obtain an understanding behind the real valuation behind the business. I discussed how AT&T (T) and Coca-Cola (KO) appeared cheaper than usual. Today, I will discuss another example of a situation, where I had to dig deeper, before obtaining the full picture behind Abbott Lab...  

ABBOTT PARK, Illinois, April 11, 2012 /PRNewswire/ -- HUMIRA Becomes First and Only Self-injectable Biologic Therapy for the Treatment of Moderately to Severely Active UC in AdultsAbbott (NYSE: ABT) today announced that the European Commission has approved HUMIRA(adalimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate...  

Abbott Laboratories is being forced to "contribute" $1.6 billion to Federal and State debt because Abbott marketed its drug Depakote to its customers for uses other than those that the incompetent overlords at the FDA deemed fit. As far as I can tell—and please feel free to email me if you know otherwise—there don't seem [...]  

Abbott Laboratories (NYSE:ABT) has encountered a delay in its bid for U.S. regulatory approval to expand the uses of its blockbuster anti-inflammatory drug Humira to include treatment of the bowel disease ulcerative colitis. Abbott received a ...  

Fitch Ratings has placed Abbott Laboratories' Long-term ratings on Negative Watch. In addition, Fitch has affirmed ABT's Short-term ratings at 'F1'. A full list of ABT's ratings follows at the end of this press release.  

The city approved an incentive package this week worth more than $1.2 million to allow Abbott Laboratories to continue building its $270 million plant on S. County Road 25A. The incentives, which will cost the city $1,229,190, include building an East-West access road on the south side of the Abbott lot. The road is being partially funded by the state and partially from the income tax fund we will...  

About Acute Kidney Injury Associated with Major Cardiac Surgery Acute kidney injury (AKI) is known to be associated with increased short- and long-term mortality and co-morbidity, as well as prolonged hospitalization and permanent decline in renal function.  

ABBOTT PARK Ill., April 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL),  

Pharmaceutical giant Abbott Laboratories has agreed to pay the government a total of $1.6 billion to settle claims that it illegally promoted off-label uses of its drug, Depakote. As part of the Abbott settlement, the company will pay a $700 million criminal fine and will plead guilty to one misdemeanor,...... Continue reading this article, and get more legal news and information, at FindLaw.com.  

Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration. Deputy Attorney General James Cole said Monday the settlement reflects the determination ...  

Here's a PR Newswire post that ran in a local news' .com site:An infant formula product produced by Abbott Laboratories (ABT.NYSE), failed to reach China national safety standards and tested worst among a selection of six infant formula powders sold on the Chinese market, according to a research report released by Hong Kong-based research house CER Research on Thursday.] The release of the research report on Abbott's Similac Stage 1 milk...  

Abbott Laboratories Abbott Laboratories Latest from The Business Journals U.S. manufacturing picks up pace Accelr8 Technology to get major private-equity investment, new execs St. Jude Medical, Abbott Laboratories expand marketing partnership ...  

HONG KONG, March 22, 2012 /PRNewswire-Asia/ -- An infant formula product produced by Abbott Laboratories (ABT.NYSE), failed to reach China national safety standards and tested worst among a selection of six infant formula powders sold on the Chinese market, according to a research report...  

HONG KONG, March 23, 2012 /PRNewswire-Asia/ -- CER Research, a Hong Kong-based corporate research and investigative company, Friday issued a statement responding to allegations from Abbott Laboratories (NYSE:ABT) with regard to a report released by CER Research on March...  

Attorney General Mike DeWine says Ohio will get more than $10.7 million for its share of a settlement between dozens of states and Abbott Laboratories. The pharmaceutical company was accused of promoting the anti-seizure drug Depakote for uses that were not federally approved, resulting in false Medicaid claims. Authorities said Monday that Abbott pleaded guilty and agreed to pay $1.5 billion. More than half of that amount is civil...  

McGrawWASHINGTON (Legal Newsline) – Abbott Laboratories is paying $1.5 billion to resolve criminal and civil liability arising from its marketing of the prescription drug Depakote.The federal government will receive $700 million in the agreement, while states will split $700 million. West Virginia Attorney General Darrell McGraw said the state will get $1 million.Abbott allegedly promoted its drug to control agitation and aggression in...  

Massachusetts will get $19.8 million as part of a pair of multi-state settlements with Illinois drug company Abbott Laboratories, which agreed to pay a total of $900 million and plead guilty to violating a federal drug law to resolve charges of illegal off-label marketing. The settlements revolve around the company’s promotion of the anti-seizure medication Depakote for off-label uses over a 10-year period. In one, Abbott will pay the states...  

Washington state will receive $7 million from multistate settlements with Abbott Laboratories over allegations the company illegally promoted an anti-seizure drug.

Abbott has agreed to pay $1.5 billion over the illegal off-label marketing of its anti-seizure drug Depakote.  

Utah part of $1.6B settlement with Abbott over seizure drug STAFF AND NEWS SERVICES Published May 7, 2012 07:26PM MDT Abbott Laboratories will pay a record $1.6 billion to settle federal and state claims, including $1 million to Utah, that it improperly marketed the neurologic medication Depakote for off-label uses, the company said Monday. The Utah Division of Consumer Protection said the funds will go to benefit consumer education...  

OLYMPIA –Washington state will receive $7 million from multistate settlements with Abbott Laboratories over allegations the company illegally promoted an anti-seizure drug. Abbott has agreed to pay $1.5 billion over the illegal off-label marketing of its anti-seizure drug Depakote.  

Arkansas Attorney General Dustin McDaniel has announced the settlement of two cases involving the pharmaceutical company Abbott Laboratories.  

NEW YORK (TheStreet) -- The following stocks go ex-dividend Wednesday, meaning an investor must purchase the shares Tuesday to qualify for the next dividend payment: Abbott Laboratories, Buckle, Freeport-McMoran, Foot Locker, General Dynamics, Goldcorp, Morningstar and Yum Brands. Each of the stocks received a buy rating from TheStreet Ratings. Abbott Laboratories ... Click to view a price quote on MORN...  

NEW YORK (TheStreet) -- Shares of these stocks hit 52-week highs on Wednesday: Abbott Laboratories, J.B. Hunt Transportation and G Services. Abbott Laboratories The pharmaceutical company reported Wednesday encouraging results from a hepatitis C treatment study that showed a cure rate of greater than 90% from a three-drug, all-oral regimen. ... Click to view a price quote on ABT...  

A year after a major study called into question whether prescribing an Abbott Laboratories’ pill designed to raise levels of good cholesterol protected against heart attacks and strokes, doctors are moving away from prescribing the treatment.  

Ohio will receive $14.5 million from settlements against Abbott Laboratories Abbott Laboratories Latest from The Business Journals Oregon nabs M in pharma settlement Colorado to receive .7M from Abbott settlement Abbott Labs in .5B settlement ...  

Kentucky will receive $4.6 million as part of a legal settlement with Abbott Laboratories.  

Medical device and drugmaker Abbott Laboratories has agreed to pay a $100 million national settlement over the illegal off-label marketing of its anti-seizure drug Depakote (DEP-uh-coat). Medical device and drugmaker Abbott Laboratories has agreed to pay a ...  

Active individuals require specific amounts of carbohydrates, proteins and fats to fuel muscles, build strength and recover after physical ... goals and be 100 percent confident they are getting a safe, science-backed product." EAS products are tested ...  

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ... ABT), Medtronic (NYSE: MDT), Boston Scientific (NYSE: BSX) and Big Lots Inc. (NYSE: BIG). (Logo: http://photos.prnewswire.com ...  

The Development Financing Advisory Council has approved a $1.5 million loan for Abbott Laboratories through the Ohio Department of Development. Abbott will use the funding for the purchase of machinery and equipment at their new Tipp City facility. With the money, the compnay has committed to more than 240 new, full-time jobs with an average wage of $24.21 an hour. “Abbott Labs’ decision to build a new facility in Tipp City is welcome news...  

Ohio beat Canada and Indiana in landing the $270 million Abbott Laboratories nutritional drinks plant, Ohio Gov. John Kasich and U.S. House Speaker John Boehner said Monday at the plant’s ceremonial groundbreaking. The plant will employ 240 workers with room to grow, Abbott and public officials also said. And Kasich expressed confidence that Ohio would recoup its incentives investment into the plant in little more than a year. “It’s a good...  

Two global companies, both in the Chicago area, announced the names of spinoff brands yesterday. That’s two opportunities to observe that it isn’t only small, underfunded startups that make bad naming decisions. Exhibit A: Health-care company Abbott Laboratories will name its new pharmaceutical company AbbVie. According to the Abbott press...  

OLYMPIA, Wash. (AP) -- Washington state will receive $7 million from multistate settlements with Abbott Laboratories over allegations the company illegally promoted an anti-seizure drug. Abbott has agreed to pay $1.5 billion over the illegal off ...  

NORTH CHICAGO — Abbott Laboratories' first-quarter net income grew more than 13 percent on higher sales of biotech drugs, nutritional formula and diagnostic tests. The drug and medical device maker on Wednesday reported net income of $1.2 ...  

Washington Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.  

Abbott Laboratories said Monday it will pay $1.6 billion to settle federal and state claims that it illegally marketed the anti-seizure medication Depakote for uses not approved by the Food and Drug Administration.  

Abbott has agreed to change how it markets Depakote and cease promoting it for unapproved uses.  

Brandner v. Abbott Laboratories, Inc.Lexology (registration)The plaintiff sued Abbott Laboratories after it recalled Similac baby formula following its discovery of beetles in a finished batch of formula. The plaintiff alleged that her child suffered gastrointestinal problems after ingesting formula from the ...  

DUBLIN, Apr 04, 2012 (BUSINESS WIRE) -- Dublin - Research and Markets (http://www.researchandmarkets.com/research/c211ff87/abbott_laboratorie) has announced the addition of the "Abbott Laboratories Inc in Packaged Food (World)" company profile to their offering.  

San Diego, CA: Determining whether a drug's side effects ... cover the cost of an investigation by the Justice Department into allegedly illegal marketing of Depakote. Attorneys general in eight states have also joined forces to investigate whether Abbott ...  

Medical device and drugmaker Abbott Laboratories (NYSE: ABT) said it will pay $1.6 billion to settle federal and state claims regarding illegal off-label sales and marketing of its neurologic medication Depakote.  

Options Trader Alert for Abbott Laboratories (ABT)AVAFINNEW YORK (AVAFIN) -- Options traders were heavily trading call contracts during the last trading session establishing a new 3-month call volume record. A total of 5196 put and 18560 calls were traded where call contracts outnumbered puts 3.6:1, ...and more »  

With this approval in Japan, XIENCE PRIME is available in all of the major markets worldwide, including the United States, Europe, China, India and other ... for cardiac and vascular care, including products for coronary artery disease, vessel closure ...  

AsiaOneConsider avoiding Abbott Laboratories on concerns over milk powder quality in ...China Economic ReviewThe news: CER Research issued a report today indicating that milk formula producer Abbott Laboratories fails to meet quality standards in the Greater China region, and Chinese media has reported that a container of Abbott Laboratories formula was ...Abbott Laboratories Chinese Infant Formula Violates China National Standards...  

HARTFORD, CT - Attorney General George Jepsen said Connecticut will receive approximately $6 million from federal and state civil and criminal settlements announced Monday with Illinois-based Abbott Laboratories over allegations the company promoted sales ...  

Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.  

TEXT-S&P keeps Abbott Laboratories ratings on watch negativeReutersIts nutritional business, with the well-recognized Similac brand of infant nutritionals, has positions in mature and emerging markets. The worldwide diagnostics unit has strong positions in immunochemistry assays, hematology, and molecular diagnostics.and more »  

Drugmaker Abbott Laboratories has been fined $1.6 billion for marketing its anti-seizure medication Depakote for other unauthorized uses, US authorities and the company announced Monday. The Department of Justice said Abbott pleaded guilty and would pay a ...  

COLUMBUS, Ohio — Attorney General Mike DeWine says Ohio will get more than $10.7 million for its share of a settlement between dozens of states and Abbott Laboratories. The pharmaceutical company was accused of promoting the anti-seizure drug Depakote ...  

Ohio will receive $14.5 million from settlements against Abbott Laboratories, part of $1.5 billion and $100 million agreements with the federal government and most states across the country, the Dayton Business Journal reported. The settlements stem from ...  

(RTTNews) - Abbott Laboratories (ABT: News ) Monday reached a settlement with U.S. authorities to resolve all outstanding issues regarding a probe of past sales practices relating to its neurologic medication Depakote. As part of the settlement, Abbott ...  

RICHMOND, Va. — Health care company Abbott Laboratories has agreed to pay a $100 million national settlement over the illegal off-label marketing of its anti-seizure drug Depakote (DEP-uh-coat). Virginia Attorney General Ken Cuccinelli announced the ...  

Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.  

Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.  

Health care company Abbott Laboratories (ABT) pleaded guilty and agreed to pay $1.6 billion Monday to settle federal and state allegations that it promoted the anti-seizure drug Depakote for uses that weren't approved by the Food and Drug Administration.  

Abbott Laboratories said on Monday it has agreed to pay $1.6 billion to resolve civil and criminal allegations related to past sales practices involving its anti-seizure drug Depakote. The diversified healthcare company has also agreed to plead guilty to ...  

Medical device and drugmaker Abbott Laboratories has agreed to pay a $100 million national settlement over the illegal off-label marketing of its anti-seizure drug Depakote (DEP-uh-coat). Virginia Attorney General Ken Cuccinelli announced the settlement ...  

COLUMBUS, Ohio (AP) -- Attorney General Mike DeWine says Ohio will get more than $10.7 million for its share of a settlement between dozens of states and Abbott Laboratories. The pharmaceutical company was accused of promoting the anti-seizure ...  

LITTLE ROCK, Ark. (AP) - Arkansas Attorney General Dustin McDaniel has announced the settlement of 2 cases involving the pharmaceutical company Abbott Laboratories. McDaniel said Tuesday that Abbott will pay Arkansas a total of $3.03 million as part of a $ ...  

This breakthrough combination allows for identification and characterization of broad groups ... 03/22 DJ WSJ BLOG/Health : Medical Group Blinks Amid Criticism Over Drug-Data Disclosure 03/22 DJ European Medical Group Changes Drug Data-Release Policy ...  

WASHINGTON — The pharmaceutical company Abbott Laboratories said on Monday that it had reached an agreement with the federal and nearly all state governments to pay $1.6 billion in connection with its illegal marketing of the anti-seizure drug ...  

CNN - Found 1 hour agoWashington (CNN) -- Abbott Laboratories has pleaded guilty and agreed to pay $1.6 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote, the U.S. Justice Department said Monday. Acting Associate Attorney General Tony West ... Abbott Labs Agrees to Pay $1.5 Billion Over Depakote - New York Times...  

PIERRE, S.D. (AP) -- Attorney General Marty Jackley says South Dakota will get about $1.3 million as part of a settlement between the U.S. government and Abbott Laboratories related to the anti-seizure drug Depakote. The company has pleaded ...  

Abbott Laboratories (ABT) agreed to pay $1.6 billion and to plead guilty to a criminal misdemeanor violation of a federal drug law following allegations that the company improperly promoted antiseizure drug Depakote for unauthorized uses. The ...  

Missouri will receive $1.9 million, and Illinois will receive $20 million, as part of $1.6 billion in settlements by Abbott Laboratories with federal officials and those of most states over allegations of illegal off-label marketing of its Depakote drug, Illinois Attorney General Lisa Madigan and Missouri Attorney General Chris Koster said today. Their federal counterparts and attorneys general from 43 other states and the District of...  

Enhanced Online News)--Halunen & Associates, a Minneapolis law firm, represents one of the whistleblowers in the $1.5 billion settlement with Abbott Laboratories announced today by the Department of Justice in a case involving government fraud. The case ...  

CHICAGO (MarketWatch) -- The Justice Depart said Monday that Abbott Laboratories has pleaded guilty and will pay a total of $1.5 billion to settle its criminal and civil cases over its marketing of the drug Depakote. Federal officials had charged the company with promoting the substance for unapproved uses. The payments, which the Department said are the second largest ever by a pharmaceutical company, include a criminal fine and forfeiture...  

Abbott Laboratories Inc. has agreed to a $1.6 billion settlement of civil and criminal charges brought by 45 states and the federal government after pleading guilty to the off-label marketing of its anti-seizure drug Depakote. According to a ...  

Abbott Laboratories’ guilty plea and related $1.5 billion payout to settle allegations it sold ... This time, Abbott will pay $800 million to settle civil allegations that will result in a sum that will be divvied up among the U.S. Treasury ...  

 Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook -- First Quarter Ongoing EPS of $1.03, Up 13.2 Percent -- -- Raises Ongoing EPS Outlook for ...  

("Abbott To Pay $1.6B To Settle Depakote Charges," at 1:15 p.m. EDT, misstated the number of states involved in the settlement, in the second paragraph. The correct version follows:) Abbott Laboratories (ABT) agreed to pay state and federal ...  

Abbott Laboratories said it will pay $1.6 billion to settle federal and state claims that it improperly marketed the neurological medication Depakote for off-label uses. Abbott will pay $800 million to resolve civil allegations split among ...  

Abbott Laboratories (ABT) said it reached an agreement to pay $1.6 billion to settle federal and state claims resulting from an investigation into its epilepsy medication Depakote, the second-largest drug-marketing settlement in U.S. history.  

Maryland is slated to receive $1.8 million for its part in a national settlement with Illinois-based Abbott Laboratories over allegations of illegal drug marketing, Attorney General Douglas F. Gansler said Monday. Gansler's office said the ...  

Global pharmaceutical giant Abbott Laboratories has agreed to pay federal and state governments $1.6 billion in criminal and civil fines for illegally promoting unapproved uses of its drug Depakote, including to sedate elderly patients in ...  

Abbott is the largest drugmaker by market share in India after it acquired Piramal Healthcare’s formulations business in 2010 for $3.72 billion Bangalore: US drug maker Abbott Laboratories said on Thursday it will establish a nutrition research and ...  

The report gave details of five tests conducted on the Abbott product, bought in Hong Kong in December and tested by one of the world's top food testing laboratories in Germany, with comments from named top experts. The product, Similac Stage 1 ...  

REUTERS - Abbott Laboratories (ABT.N) has partnered Indian biotechnology company Biocon Ltd (BION.NS) to develop nutrition products for India, as the U.S. drugmaker steps up its push to tap a potentially big market. Abbott will build a research ...  

As Abbott Laboratories prepares to get down to basics as a consumer-products company, it is pinning its emerging-market ambitions in part on turmeric. And cumin and chili. Abbott, which will split with its 124-year-old drug division later this ...  

NORTH CHICAGO, Ill. (AP) -- Abbott Laboratories will spend $110 million to buy a potential kidney treatment from the privately held Danish company Action Pharma, the company said Thursday. The drug, labeled AP214, is in mid-stage clinical ...  

Abbott Laboratories Abbott Laboratories Latest from The Business Journals Follow this company chose to build ... Abbott plans to produce three products for adults, children and those with diabetes when the plant is completed in about 18 months.  

The spin off should create shareholder value. I would wait for a share pullback to accumulate shares. The stock is at a 52 week high. An appropriate entry price would be $55 - $56. Allow the stock to back down before accumulating a position.  

Abbott Laboratories has partnered biotechnology company Biocon Ltd to develop nutrition products for India ... The nutrition market in India, home to more than 1.3 billion people, is relatively nascent and valued at about $1 billion, according ...  

BANGALORE -(Dow Jones)- U.S. drug maker Abbott Laboratories (ABT) has tied up with a unit of Indian biotechnology company Biocon Ltd. (532523.BY) to set up a research and development center for nutrition products. Abbott will set up the center ...  

Abbott Laboratories (ABT) is, as far as I can tell, a wonderful company and has accomplished significant feats in the past- both for world health and for its shareholders. It is a widely held dividend aristocrat, and is respected across both the investment ...  

Abbott Laboratories has filed a citizen’s petition with the FDA in which the drugmaker asks the agency not to approve any biosimilar for its Humira treatment for rheumatoid arthritis. On what grounds? Abbott argues that the FDA would have no ...  

(Crain's) — As it prepares to split into two companies, Abbott Laboratories aims to develop basic products that play on the local flavor of emerging markets like India and China, rather than create another blockbuster drug like Humira, the ...  

May 3 (Reuters) - Abbott Laboratories has partnered Indian biotechnology company Biocon Ltd to develop nutrition products for India, as the U.S. drugmaker steps up its push to tap a potentially big market. Abbott will build a research and ...  

Abbott Laboratories Inc. pleaded guilty this week and will pay $1.5 billion to resolve its criminal and civil liability issues involving off-label promotion of the company’s [...]  

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Pharmaceutical ...  

First and foremost, Abbott Laboratories just unveiled the results of a trial evaluating a treatment in development for advanced Parkinson's disease and the results were positive. This drug lowers the "off" time of those suffering from Parkinson's ...  

WASHINGTON - Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration. The case includes a criminal fine and ...  

Nothing wrong with the first-quarter earnings numbers from Abbott Laboratories (ABT). In fact, I'd call them strong and above expectations. In fact, the only disappointment has been the market's failure to put the higher price on the shares that I think ...  

April 23 (Reuters) - Abbott Laboratories Inc and St Jude Medical Inc on Monday said they will jointly promote each others' cardiovascular products in the United States, allowing both companies to offer a full line of devices to hospitals in an ...  

(RTTNews) - Healthcare products maker Abbott Laboratories (ABT: News ) on Wednesday reported a 44 percent surge in profit for the first quarter, helped by higher sales of its drugs and nutritional products. Both revenues and ongoing earnings per share ...  

CER Research Says Abbott's Response To Similac Test Results IrresponsibleNASDAQ(RTTNews.com) - Hong Kong-based CER Research Friday said Abbott Laboratories Inc.'s (ABT) response to the report released March 22 relating to the safety of the infant formula product Similac Stage 1 was "irresponsible." The report contained results ...Abbott Laboratories Chinese Infant Formula Violates China National Standards ...Bradenton HeraldCER Research...  

Abbott Laboratories' (ABT) first-quarter earnings rose 44%, helped by continued sales growth for blockbuster anti- inflammatory drug Humira and cost-saving measures. The health-care product company's earnings exceeded analysts' expectations, and ...  

Abbott Laboratories' (NYSE:ABT) first-quarter earnings rose 44% as strong drug and nutritional sales contributed to improved margins. The health-care company also raised its full-year earnings guidance by 5 cents, now projecting $5 to $5.10 a share.  

SAN FRANCISCO -- Attorney General Kamala D. Harris today announced two historic settlements with Abbott Laboratories over the illegal off-label marketing of its Depakote drug.  

In today's world, most companies span several regions and sell across the world ... multinational corporations that have already established a presence in their home markets, much of their future growth comes from abroad.  

Currently, Abbott Laboratories' stock is trading at around $61. Compared with recent figures ... in that it has the potential to considerably improve patients' quality of life, causes Abbott Laboratories to appear a sympathetic company.  

ABBOTT PARK — Abbott Laboratories’ next-generation Xience Prime drug-eluting stent has received approval from Japan, the second-largest health-care market in the world, the company said Monday. With Japanese approval, Xience Prime, which features an ...  

(RTTNews.com) - Abbott Laboratories (ABT) announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel or LCIG. The company said that the study ...  

Every year, Americans pay $700 million more for cholesterol-lowering drugs than they need to. The reason? Abbott Laboratories. Abbott Labs is a pharmaceutical company based in Illinois. About a decade ago, in 2000, it faced a problem. The company had recently acquired exclusive rights to sell Tricor-1, a cholesterol-fighting drug. It was profitable, which was nice, but the best part was this: It ...  

Abbott Laboratories (ABT), splitting into a drugmaker and a diversified health-care business, reported net income that beat analysts’ estimates and raised its 2012 forecast as sales jumped more than expected for its top product. First-quarter ...  

Few relapses were reported among patients taking Abbott Laboratories (ABT)’ experimental hepatitis C treatment, according to a study. The Abbott-funded research, dubbed Pilot, found that 10 of 11 patients who hadn’t received prior treatment ...  

(Reuters) - Humira, the best-selling arthritis drug that forms the cornerstone of Abbott Laboratories' pharmaceutical business, has been approved in Europe for ulcerative colitis, the U.S. drugmaker said on Wednesday. The green light from the European ...  

Abbott Laboratories (ABT) reported positive results from a Phase 3 trial evaluating ... LCIG, which is currently being evaluated in additional Phase 3 trials in the U.S., is approved in 40 countries outside the U.S. Abbott's diverse portfolio ...  

North Chicago-based Abbott Laboratories said it earned $1.24 billion in the first quarter, a nearly 44 percent increase from the year-ago quarter, and raised its full-year earnings forecast. Earnings per share at the pharmaceutical and medical ...  

Abbott Laboratories' (ABT) first-quarter earnings rose 44%, helped by continued sales growth for blockbuster anti- inflammatory drug Humira and cost-saving measures. The health-care product company's earnings exceeded analysts' expectations ...  

Abbott Laboratories (ABT), splitting into a drugmaker and a diversified health-care business, reported earnings that beat ... when the company took charges for acquisitions and an accounting change. Earnings excluding one-time items were $1 ...  

ABBOTT PARK — Abbott Laboratories has obtained European Union approval to market its rapid, Plex-ID instrument, along with three assays for use on the system. Plex-ID, which is based on molecular diagnostic technologies, addresses a need for rapid ...  

Abbott Laboratories reported better-than-expected earnings on Wednesday as sales surged of Humira, an injectable arthritis medicine, underscoring the company’s reliance on it. Humira, introduced by Abbott a decade ago, keeps picking up steam.  

TIPP CITY — The city approved an incentive package this week worth more than $1.2 million to allow Abbott Laboratories to continue building its $270 million plant on S. County Road 25A. The incentives, which will cost the city $1,229,190, include ...  

Abbott Laboratories' $9-billion arthritis drug Humira is set to take the crown as the world's top-selling medicine this year, highlighting the dominance of costly biotechnology products as revenues from old-style pills decline. Neither of last ...  

Abbott Laboratories (ABT) announced last fall that it would be spinning off its proprietary pharmaceutical business from its diversified medical products business. "Abbott expects the post-spin-off diversified medical products company, which will retain ...  

Council Votes Unanimously to Formalize Agreement Between City and Abbott ...TippNews DAILYCouncil voted unanimously on a resolution formalizing the agreement between the city and Abbott Laboratories. As part of the agreement, the city will be responsible for the construction of a new road—to be called Abbott Park Way—and the extension of ...Tipp City approves $1.2M incentives for Abbott plantDayton Daily Newsall 2 news articles »  

24 Hours VancouverAbbott Drugs Suppress Hepatitis C Virus In 2 StudiesWall Street JournalBy Peter Loftus Of DOW JONES NEWSWIRES Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies. The results unveiled Wednesday could reinforce Abbott's position as a key player ...Abbott Hepatitis C Therapy Cures Patients Failed by Other DrugsBloombergAbbott Hepatitis C Therapy...  

BloombergAbbott Drugs Suppress Hepatitis C Virus in StudiesWall Street JournalBy PETER LOFTUS Experimental drugs from Abbott Laboratories suppressed the hepatitis C virus in most patients in two small, midstage studies. The results unveiled Wednesday could reinforce Abbott's position as a key player in an industry race to bring ...Abbott Hepatitis C Therapy Works After Other Drugs FailSan Francisco ChronicleAbbott hepatitis C combo impressive...  

Abbott Laboratories (ABT) (ABT)’ experimental hepatitis C treatment cured 47 percent of patients who had failed to rid themselves of the virus using therapies now on the market, according to a company study. The research, reported today at the ...  

Experimental drugs from Abbott Laboratories (ABT) suppressed the hepatitis C virus in most patients in two small, mid-stage studies. The results unveiled Wednesday could reinforce Abbott's position as a key player in an industry race to bring ...  

Abbott Laboratories (ABT) had a strong year in 2011. The company made advancements in its pipeline, launched new products, increased its earnings, dividends, and announced splitting up into 2 companies by the end of 2012. In the last year, the company's ...  

Two Chicago area CEOs — Miles White at Abbott Laboratories and Jim Skinner at McDonald’s — are among 30 of the world’s best company leaders, according to Barron’s annual list. Former Chicagoan Jamie Dimon of New York-based JPMorgan Chase bank and ...  

("Abbott Drugs Suppress Hepatitis C Virus In 2 Mid-Stage Studies" published at 10:07 a.m. EDT incorrectly described Abbott's role in developing the drug ABT-450. A corrected version follows.) Experimental drugs from Abbott Laboratories (ABT ...  

Dividend.comPfizer Rises After Goldman Raises Potential for Full BreakupBusinessWeek“We see these moves as first steps in a potential full- scale breakup,” akin to the split now taking place at Abbott Laboratories (ABT) (ABT), Rubin wrote. Abbott, based in Abbott Park, Illinois, said Oct. 19 it plans to divide into two publicly traded ...Is a Pfizer Breakup in the Cards? How Much Would it be Worth?Barron's (blog)Pfizer Moves Higher Amid...  

Abbott Laboratories (ABT) reports its first quarter earnings on Wednesday, April 18, 2012.  

As Abbott Laboratories prepares to get down to basics as a consumer-products company, it is pinning its emerging-market ambitions in part on turmeric. And cumin and chili.  

Shares of Abbott Laboratories (NYSE: ABT) rose Wednesday after the health care products maker beat first-quarter expectations by reporting a 43 percent jump on higher emerging markets sales and raising its full-year earnings guidance.  

News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to...  

Abbott Labs, Allegiant Travel, Biogen, DDI Among Stocks Hitting 52-Week HighsWall St. Cheat SheetBy Derek Hoffman Abbott Laboratories (NYSE:ABT): Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C at the International Liver Congress 2012. In the study known as “Co-Pilot,” ...and more »  

Abbott, Acuity, Monsanto, SanDisk, WebMD: U.S. Equity MoversSan Francisco ChronicleStock symbols are in parentheses and prices are as of 10:45 am Abbott Laboratories (ABT US) advanced 1.2 percent to $61.90 and rose to $62.57 earlier, the highest intraday price since at least July 1980. The drugmaker's experimental hepatitis C ...and more »  

Abbott Laboratories (ABT) (ABT) said the European Commission approved its Humira injection for moderately to severely active ulcerative colitis in adults who haven’t responded well to conventional treatment. The decision makes Humira the first ...  

WASHINGTON — Drugmaker Abbott Laboratories has been fined $1.6 billion for marketing its anti-seizure medication Depakote for other unauthorized uses, US authorities and the company announced Monday.  

LONDON -(Dow Jones)- Abbott Laboratories' (ABT) top-selling arthritis drug Humira has been approved in Europe for ulcerative colitis, the U.S. drug maker said Wednesday. The decision makes Humira the first and only self-injectable biologic ...  

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) said Tuesday a late stage trial of its investigational compound levodopa-carbidopa intestinal gel showed positive results in patients...  

(Crain's) — CEO Miles White is expected to offer investors further guidance on the spinoff of the research-based drug business when the North Chicago firm releases first-quarter earnings Wednesday.  

(Reuters) Apr 11 - Humira (adalimumab), the best-selling arthritis drug that forms the cornerstone of Abbott Laboratories' pharmaceutical business, has been approved in Europe for ulcerative colitis, the U.S. drugmaker said on Wednesday.  

Just the facts, Fool.